Madrigal Pharmaceuticals Inc

1MDGL

Company Profile

  • Business description

    Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

  • Contact

    200 Barr Harbor Drive
    Suite 200, Four Tower Bridge
    West ConshohockenPA19428
    USA

    T: +1 267 824-2827

    E: [email protected]

    https://www.madrigalpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    528

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,571.4040.30-0.47%
CAC 407,864.4446.05-0.58%
DAX 4023,999.17123.23-0.51%
Dow JONES (US)42,038.68178.240.43%
FTSE 1008,739.2647.20-0.54%
HKSE23,544.31283.47-1.19%
NASDAQ19,036.52163.870.87%
Nikkei 22536,985.87313.11-0.84%
NZX 50 Index12,662.2540.85-0.32%
S&P 5005,871.0126.400.45%
S&P/ASX 2008,348.7038.10-0.45%
SSE Composite Index3,380.197.39-0.22%

Market Movers